Relationship of LDL-C & LDL-P. Lipoprotein Particles LipoScience 2007 NON-POLAR LIPID CORE Cholesterol Ester Triglyceride POLAR SURFACE COAT Phospholipid.

Slides:



Advertisements
Similar presentations
The Skinny on Trans Fats
Advertisements

Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia N Engl J Med Mar 11;362(10): Paul W. Ladenson, M.D., Jens D.
Lipoprotein Management. Step 1: Assess clinical CHD risk (Very-High, High, Moderately-High, Moderate, Low Risk) Step 2: Establish goals of therapy appropriate.
Plant Sterols – a product case study
Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol VA-HIT Rubins, HB, et.
Metabolic & Endocrine Disease Summit Dyslipidemia and Current Guidleines for Lipid Management Thursday July 28, 2011 Orlando, FL Joyce L. Ross, MSN, CRNP,
COMPOSITION OF LIPIDS Lipoproteins Apolipoproteins Lipoproteins Apolipoproteins Cholesterol Protein Triglyceride Phospholipid.
By- Katherine Kauffman Vanessa Witmer. Brief Steroid Information Steroids are the third major class of lipids. Their structure is basically four rings.
Lipoprotein Structure and Function
Dyslipoproteinemia and Atherosclerosis
Weng TC, et al. J Clin Pharm Ther 2010;35:
Aims 1.Outline the structural diversity of lipids. 2.Examine the biophysical characteristics of lipids. 3Outline the biochemical synthesis of fatty acids,
 The third major class of lipids  The three cyclohexane rings (A, B, C) are connected to a cyclopentane ring (D).  Significantly different structure.
1 LIPID TRANSPORT Lipoproteins Lipids are transported in the blood as lipoproteins are soluble in water because the surface consists of polar lipids.
SECONDARY PREVENTIONS Jaimon Stucki MS-1 PSCOM. Blood Draw.
13.9 Steroids Kyleigh Moyer Taylor Raker. What are Steroids?  A compound containing this ring formation  Three cyclohexane rings  Another cyclohexane.
organic solvent H2OH2O lipids everything else lipids everything else = = "nonhydrolyzable lipids"
13.9 Cholesterol.
Third major class of lipids. It is a compound that contains three cyclohexane rings A. Cholesterol The most abundant steroid in the human body. The most.
Baseline Characteristics of Cases, Controls, and Entire VA-HIT Population James D. Otvos, et al, Circulation 2006;113:
 Main lipids in the blood are the triglycerides and cholesterol.  Insoluble in the water.  Transport in the blood is via lipoproteins.
Kastelein JJ, et al. Circulation 2008;117: On-Treatment Values of Lipids, Apolipoproteins, and Their Ratios in Both Treatment Groups of TNT and IDEAL.
Kristin Miller Caleb Conrad 13.9 What Are Steroids.
L IPOPROTEINS. W HAT ARE LIPOPROTEINS ? Lipoproteins are molecules produced in the body and act as lipid transporters They consist of: Triglycerides Protein.
Lipids - 4 Lipoprotiens 1Dr. Nikhat Siddiqi. Lipoproteins Group of molecular complexes found in the blood plasma of mammals. The plasma lipoproteins are.
Lipoprotein Structure and Function LP core Triglycerides Cholesterol esters LP surface Phospholipids Proteins Cholesterol Are conjugated proteins, composed.
Triglycerides The major lipids of the body (triglycerides, cholesterol, phospholipids and glycolipids) play a variety of biologic roles. They serve as:
Parameters BD PP CP TC (mg. dl-l) ± * ± 5.8
Supplemental Figure 1 A B C D E F
Should we move from Lipids to Lipoproteins, from Dyslipidemia to Dyslipoproteinemia in future guidelines for CVD?
Director, Lipid Research Center The Johns Hopkins Medical Institutions
HDL Particle Number Is It a Key to Understanding HDL Cardiovascular Risk and Therapy? Jim Otvos, PhD Chief Scientific Officer LipoScience, Inc. Adjunct.
Atherosclerosis, Plaque Imaging
Transport of lipids Title slide - the transport of lipids. Important because they aren’t water soluble.
Arterioscler Thromb Vasc Biol
Biogenesis of Nascent High Density Lipoprotein Particles
HDL and Atherosclerosis
End point Muraglitazar 5 mg plus metformin (n=569)
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:
Review of Cholesterol and Lipoproteins
Figure 7 Mendelian randomization of overlapping exposures
Biogenesis of Nascent High Density Lipoprotein Particles
Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 
Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 
Effect of evolocumab on lipoprotein particles
Nat. Rev. Cardiol. doi: /nrcardio
Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study) 
A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia  Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki.
Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis  Robert Wolk, MD, PhD, DSc, Ehrin J.
Meredith Kilgore, PhD, Paul Muntner, PhD, J
Eveline Oestreicher Stock, MD, Christine T
Description of studies for pooled analyses
Mikko Syvänne, MD, Marja-Riitta Taskinen, MD  The Lancet 
Subject Characteristics
Hajer GR et al. Atherosclerosis 2009;202:216-24
Comparison of clinical and functional parameters among non-responders (=1) and responders (≥4) among healthy elderly and elderly patients with T2DM. Comparison.
Figure 1 The major pathways of lipid metabolism
New insights into lipid metabolism in the nephrotic syndrome
Baseline Patients with coronary artery disease (CAD) and high (n=98) versus normal (n=1512) high-density lipoprotein (HDL) levels Doreen DeFaria Yeh, et.
Comparison of clinical and functional parameters between the CMV+ and CMV− participants in the healthy elderly and elderly patients with T2DM. Comparison.
Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication.
(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.
Change in (A) total cholesterol; (B) LDL-cholesterol; (C) HDL-cholesterol and (D) triglycerides over 5 years in response to 12-week intensive lifestyle.
Schematic representation of dyslipidaemia of metabolic syndrome.
Baseline characteristics of the 1,842 men without coronary heart disease and the 230 men with a first coronary heart disease event during the 13-year.
Reverse cholesterol transport CETP is key in remodeling of HDL
Correlation between progranulin (dependent variable) and CKD stage adjusted for age and sex, as well as DBP, WHR, triglycerides, HDL cholesterol, LDL cholesterol,
Plasma lipid exchange. Plasma lipid exchange. In the presence of increased concentrations of VLDL in the circulation, cholesteryl ester transfer protein.
Individual lipid measures for high-carbohydrate (n=10) and low-carbohydrate (n=10) ultra-endurance athletes. Individual lipid measures for high-carbohydrate.
FIGURE 1 Results for primary meta-analysis of controlled trials for the effects of walnut-enriched compared with ... FIGURE 1 Results for primary meta-analysis.
Presentation transcript:

Relationship of LDL-C & LDL-P

Lipoprotein Particles LipoScience 2007 NON-POLAR LIPID CORE Cholesterol Ester Triglyceride POLAR SURFACE COAT Phospholipid Free cholesterol Apolipoprotein

At the same LDL cholesterol, with the same-size LDL particles (at any triglyceride level) Up to 40% More Particles Less Cholesterol Carried Per Particle Normal Cholesterol Carried Per Particle 100 mg/dL Otvos JD et al. Am J Cardiol 2002;90(suppl):22i-29i Among Individuals With The Same LDL-C Level, The Number of LDL Particles Varies Cromwell WC et al. J Clin Lipidology. 2007;1(6): Cholesterol Balance

HDL Cholesterol (mg/dL) LDL Cholesterol LDL Particles LDL Particles (nmol/L) Triglycerides (mg/dL) LDL Particles LDL Cholesterol LDL Cholesterol (mg/dL) Relations of LDL Particles and LDL Cholesterol to Levels of HDL Cholesterol and Triglycerides Framingham Offspring Study Cromwell WC and Otvos JD. Curr Athero Reports 2004;6:

<5 th 20 th 50 th 80 th LDL-C (mg/dL) Framingham 1 < Measured ApoB (mg/dL) Framingham 1 < NMR LDL-P (nmol/L) Framingham 1 < MESA 2 < Population Equivalent Cutpoints for Alternate LDL Measures (LDL-C, Measured Apo B and NMR LDL-P) 1 Contois, et al. Clinical Chemistry 2009;55: Cromwell WC. Clinical Challenges in Lipid Disorders. Oxford:Clinical Publishing, 2008:

The cholesterol in LDL (LDL-C) does not equate to the number of LDL particles (LDL-P) because the cholesterol content per LDL particle is highly variable. Concordance and discordance refer to when LDL-C and LDL-P levels agree or disagree. – When LDL-C and LDL-P are concordant (ie., equally high or low), either LDL measure is an equally good guide to LDL treatment decision-making. – When LDL-C and LDL-P are discordant (ie., one is lower or higher than the other), LDL-P may be considered to aid in clinical management of LDL related risk for CVD. Alternate Measures of LDL Quantity are Not Equivalent 1 Davidson, et al. J Clin Lipidol 2011;5: